Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EMEA supports use of rosiglitazone for type 2 diabetes

Oct. 25, 2007

New therapeutic agents for metabolic disorders reported in recent patents

Oct. 25, 2007

Mochida Pharmaceutical receives approval in Japan for Dinagest for endometriosis

Oct. 23, 2007

Levemir approved in Japan for type 1 and 2 diabetes

Oct. 23, 2007

Abbott and Solvay sign Simcor copromotion agreement in U.S.

Oct. 23, 2007

Dara BioSciences and Bayer sign metabolic disease alliance

Oct. 23, 2007

Savient makes progress in phase III trial of Puricase for treatment-failure gout

Oct. 23, 2007

Novel agents for treating diabetes disclosed in recent patent literature

Oct. 22, 2007

Isis adds new drug, ISIS-388626, to pipeline for the treatment of type 2 diabetes

Oct. 22, 2007

ConjuChem reports final results of PC-DAC:Exendin-4 phase I/II trial

Oct. 22, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...